PRTA Insider Trading
Insider Ownership Percentage: 28.20%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00
Prothena Share Price & Price History
Current Price: $11.32
Price Change: ▼ Price Decrease of -0.82 (-6.75%)
As of 04/3/2025 05:00 PM ET
Prothena Insider Trading History
Prothena Institutional Trading History
Data available starting January 2016
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.
Read More on Prothena
Today's Range
Now: $11.32
52 Week Range
Now: $11.32
Volume
456,544 shs
Average Volume
490,748 shs
Market Capitalization
$609.32 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
Who are the company insiders with the largest holdings of Prothena?
Prothena's top insider shareholders include:
- Gene G Kinney (CEO)
- Tran Nguyen (CFO)
- Dennis J Selkoe (Director)
- Brandon S Smith (COO)
- Carol D Karp (Insider)
- Hideki Garren (Insider)
- Karin L Walker (CAO)
- Michael J Malecek (Insider)
- Wagner M Zago (Insider)
Learn More about top insider investors at Prothena.